AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
70 hedge funds and large institutions have $59.9M invested in AVEO Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 21 closing their positions.
0% more call options, than puts
Call options by funds: $6K | Put options by funds: $6K
3% less capital invested
Capital invested by funds: $61.9M → $59.9M (-$1.94M)
14% less funds holding
Funds holding: 81 → 70 (-11)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
52% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.01M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.23M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.98M |
| 4 |
VAM
Visium Asset Management
New York
|
+$801K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$525K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$4.17M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$1.68M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.26M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.18M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.14M |
AVEO Hedge Fund Activity: Q4 2013 in Review
70 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2013, worth a combined $59.9M — down 3.1% from $61.9M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AVEO and 10 opened new positions — a net loss of 11 holders — while 28 trimmed existing stakes and 23 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $6.01M. The largest seller was Palo Alto Investors, cutting an estimated $4.17M.
- 70 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2013, down from 81 in Q3 2013.
- Funds reported $59.9M of AVEO Pharmaceuticals, Inc. stock for Q4 2013, down 3.1% quarter-over-quarter.
- 10 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2013 and 21 closed out, a net change of -11 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2013 was Great Point Partners, an estimated $6.01M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q4 2013 was Palo Alto Investors, an estimated $4.17M sold.
Based on aggregated 13F filings for Q4 2013.